What is Senti Bio?
Headquartered in South San Francisco, Senti Bio operates at the intersection of computational biology and therapeutic development. The company specializes in creating gene circuits—novel DNA sequences that function as biological software—to reprogram cells. These circuits enable cells to sense, compute, and respond to complex cellular environments, providing a highly precise mechanism for treating diseases. By leveraging this synthetic biology platform, Senti Bio is positioning itself as a leader in the next wave of precision medicine, moving beyond traditional therapeutic modalities toward programmable, logic-gated cell therapies.
How much funding has Senti Bio raised?
Senti Bio has raised a total of $183.2M across 5 funding rounds:
Series A
$53M
Series B
$105M
Debt
$5.2M
Other Financing Round
$10M
Debt
$10M
Series A (2018): $53M with participation from Lux Capital, 8VC, Omega Funds, Lifeforce Capital Gp I, Goodman Capital, Amgen Business Development, Nest.Bio, New Enterprise Associates, Menlo Ventures, Allen & Company, and Pear Ventures
Series B (2021): $105M led by Matrix Partners China, Intel Capital, Leaps by Bayer, Mirae Asset Capital Co,Ltd, and Ridgeback Capital
Debt (2022): $5.2M supported by Bayer
Other Financing Round (2025): $10M featuring Celadon Partners
Debt (2026): $10M, investors not publicly disclosed
Key Investors in Senti Bio
Lux Capital
A venture capital firm specializing in early-stage and growth-stage companies at the intersection of science and technology, with a focus on frontier sectors like biotechnology.
New Enterprise Associates
A prominent venture capital firm established in 1977 that partners with entrepreneurs to build transformative businesses across various technology and healthcare sectors.
Intel Capital
The investment division of Intel, focusing on innovative startups in artificial intelligence, next-generation compute, and advanced technology sectors.
What's next for Senti Bio?
The recent influx of capital is expected to accelerate the clinical validation of Senti Bio's pipeline and enhance its internal R&D capabilities. As the company moves deeper into the enterprise-level scaling phase, the focus will likely shift toward optimizing its gene circuit manufacturing processes and expanding its therapeutic footprint. By maintaining a robust balance sheet, Senti Bio is well-positioned to navigate the capital-intensive nature of biotech development, potentially attracting further strategic partnerships or preparing for long-term commercialization milestones in the cell therapy landscape.
See full Senti Bio company page
